Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBD0333 in Locally Advanced/Metastatic Solid Tumors or Non-Hodgkin Lymphoma
NCT06292208Phase 2Recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Mar 2024
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBD0333 in solid tumor, non-Hodgkin lymphoma (NHL), sponsored by SUNHO BioPharmaceutical. Started Mar 2024; status: recruiting.
02
Drugs
IBD0333
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06292208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292208.